Get 40% Off
⚠ Earnings Alert! Which stocks are poised to surge?
See the stocks on our ProPicks radar. These strategies gained 19.7% year-to-date.
Unlock full list

Reckitt Benckiser's sales surge on coronavirus disinfectant boom

Published 30/04/2020, 07:16
Updated 30/04/2020, 09:30
© Reuters. FILE PHOTO: Products produced by Reckitt Benckiser; Vanish, Finish, Dettol and Harpic are seen in London

By Siddharth Cavale

(Reuters) - Reckitt Benckiser (L:RB) achieved record sales growth in the first quarter and predicted a stronger than expected performance in 2020 as customers stocked up on Lysol disinfectants, Mucinex cough syrup and Dettol soap ahead of the coronavirus lockdowns.

The boom in demand has come as the company had been battling intense competition in the health and hygiene industry. In February, Reckitt had announced plans to spend 2 billion pounds over the next three years to spur growth.

Reckitt's sales increase was also bigger than at Dove soap maker Unilever (L:ULVR) and Dawn detergent producer Procter & Gamble (N:PG), which also are getting a boost from people buying more soap during the crisis.

"We have seen strong consumer demand, particularly in March and April but the split between defensive buying and higher levels of underlying consumption is unclear," Chief Executive Laxman Narasimhan said in a statement.

"At this stage, it is uncertain how quickly this will change in the months ahead," he said. Narasimhan said demand could ease over the next few months as consumers work through soap and disinfectant stock in their cupboards.

The company's shares, up 5% so far this year, rose 3.2% in early trading.

"A blowout first quarter even better than expected with pantry loading and increasing usage in many of RB's categories," Jefferies analyst Martin Deboo said.

Reckitt said its 2020 performance would be better than its forecast, which called for steady progress towards mid-single-digit sales growth and adjusted operating margin declines of about 350 basis points.

First-quarter like-for-like sales rose 13.3%, easily beating analysts' estimates of 5.3% provided by the company.

The growth marked the strongest sales increase since the company was formed in 1999 through the merger of Reckitt & Colman Plc and Dutch firm Benckiser NV.

Like-for-like sales in Reckitt's hygiene business that sells Lysol disinfectants and Finish dishwashing pods rose 12.8%, while they rose 13.6% % in its Health business that sells Mucinex cough syrups and Dettol handwash.

Last week, Reckitt warned people against using disinfectants to treat the coronavirus, after U.S. President Donald Trump suggested researchers try putting disinfectants into patients' bodies.

GROWTH PLAN

CEO Narasimhan's three-year, 2 billion pound ($2.49 billion) investment plan, unveiled in February, includes cutting costs and focusing more on Greater China with the aim to return Reckitt to mid-single digit sales growth.

On Thursday, the company said the plan was underway, but some investments would be pushed back to start later in the year.

Investments are being diverted to making more hygiene and cleaning supplies and buying equipment and raw material, to help increase production, which in some cases is already up 50%.

In May, for example, the company will produce all the sanitizer it made in 2019, Narasimhan said.

Reckitt's net revenue rose 12.3% to 3.54 billion pounds in the three months ended March, beating analysts' average estimate of 3.29 billion pounds.

© Reuters. FILE PHOTO: Products produced by Reckitt Benckiser; Vanish, Finish, Dettol and Harpic are seen in London

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.